ArticleBone marrow transplantation2015
A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT.
Registry-linked trialOpen access · bronzeAbstract readComparative StudyLetter
In one paragraph
Article in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06946602 (Bu/Cy/Flu/ATG Versus Bu/Cy/ATG Conditioning Regimen in Elderly AML Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation), which is not on this map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bu/Cy/Flu/ATG Versus Bu/Cy/ATG Conditioning Regimen in Elderly AML Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation: a Prospective, Randomized, Controlled Study
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- [The causes of death in elderly patients undergoing haploidentical stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- A Novel Modified Bu/Vp16/cy/Flu/Ara-C Conditioning Regimen Enhances Outcomes for High-Risk Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Cancer medicine · 2026Article
- [Efficacy and safety of basiliximab in gastrointestinal chronic graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Review
- A novel and safe protocol for patients with severe comorbidity who undergo haploidentical hematopoietic stem cell transplantation: A single-center prospective study.Journal of translational internal medicine · 2025Article
- Comparison of allo-SCT versus consolidation chemotherapy as post-remission therapy in acute lymphoblastic leukaemia aged ≥55 years.Bone marrow transplantation · 2025Article
- A novel reduced toxicity conditioning regimen for older myelodysplastic neoplasms patients undergoing haploidentical stem cell transplantation: a prospective cohort study.American journal of cancer research · 2025Article
- [Clinical analysis of oral mucositis after secondary allogeneic hematopoietic stem cell transplantation in patients with hematological diseases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Haploidentical HSCT in the Treatment of Pediatric Hematological Disorders.International journal of molecular sciences · 2024Review
- Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study.Frontiers in oncology · 2021Article
- [Outcomes of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome without excess blasts].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Update of the "Beijing Protocol" haplo-identical hematopoietic stem cell transplantation.Bone marrow transplantation · 2019Review
- Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.Bone marrow transplantation · 2019Article
- Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation.Frontiers of medicine · 2019Review
- The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology.Journal of hematology & oncology · 2018Review
- [Strategy to improve clinical outcome of unmanipulated haploidentical stem cell transplantation without in vitro T cell depletion].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?Journal of hematology & oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Y-Q SunPeking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
L-P XuPeking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
X-H ZhangPeking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
D-H LiuPeking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
H ChenPeking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
Y WangPeking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
C-H YanPeking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
J-Z WangPeking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
F-R WangPeking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
Y-Y ZhangPeking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
K-Y LiuPeking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
X-J Huang1] Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China [2] Peking-Tsinghua Center for Life Sciences, Beijing, China.
Peking University · CNPeking University People's Hospital · CNCenter for Life Sciences · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Hematopoietic Stem Cell TransplantationAdolescentAdultAllograftsBusulfanChildChild, PreschoolComorbidityCyclophosphamideFemaleHematologic NeoplasmsHumansMaleMiddle AgedRetrospective StudiesVidarabineBusulfanCyclophosphamidefludarabineVidarabine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06946602ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.